Azenta（AZTA）株式概要
は、米国、中国、英国、欧州、アジア太平洋地域、および国際的なライフサイエンス業界向けに、生物学的および化学的化合物のサンプル探索および管理ソリューションを提供しています。 詳細
報酬
リスク分析
リスクチェックの結果、AZTA 、リスクは検出されなかった。
AZTA Community Fair Values
Create NarrativeSee what 6 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Azenta, Inc. 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | US$25.51 |
| 52週高値 | US$41.73 |
| 52週安値 | US$15.93 |
| ベータ | 1.4 |
| 1ヶ月の変化 | 11.49% |
| 3ヶ月変化 | 20.73% |
| 1年変化 | -17.12% |
| 3年間の変化 | -44.60% |
| 5年間の変化 | -72.18% |
| IPOからの変化 | 155.10% |
最新ニュース
ナラティブの更新 • Jun 23
AZTA: 2026 Execution Reset And Impairment Charges Will Support Sentiment Recovery
The latest Narrative Update on Azenta reflects a lower analyst price target, with recent Street research trimming estimates by $5 to $10 as analysts factor in updated assumptions on discount rates, revenue growth, profit margins, and future P/E expectations. Analyst Commentary Recent research on Azenta points to a more cautious stance on valuation, with reduced price targets reflecting updated views on discount rates, revenue growth, profit margins, and future P/E assumptions.ナラティブの更新 • Jun 09
AZTA: 2026 Execution Reset And Impairment Resolution Will Support Sentiment Recovery
Analysts have reduced their average price target on Azenta by $15, reflecting updated views on the stock's risk profile and earnings power. Analyst Commentary Recent Street research on Azenta has centered on lower price targets and a reassessment of the stock's risk and earnings outlook.Recent updates
ナラティブの更新 • Jun 23
AZTA: 2026 Execution Reset And Impairment Charges Will Support Sentiment Recovery
The latest Narrative Update on Azenta reflects a lower analyst price target, with recent Street research trimming estimates by $5 to $10 as analysts factor in updated assumptions on discount rates, revenue growth, profit margins, and future P/E expectations. Analyst Commentary Recent research on Azenta points to a more cautious stance on valuation, with reduced price targets reflecting updated views on discount rates, revenue growth, profit margins, and future P/E assumptions.ナラティブの更新 • Jun 09
AZTA: 2026 Execution Reset And Impairment Resolution Will Support Sentiment Recovery
Analysts have reduced their average price target on Azenta by $15, reflecting updated views on the stock's risk profile and earnings power. Analyst Commentary Recent Street research on Azenta has centered on lower price targets and a reassessment of the stock's risk and earnings outlook.ナラティブの更新 • May 25
AZTA: 2026 Guidance And Calibrated Expectations Will Support Sentiment Recovery
Analysts have reduced their price targets on Azenta by $10 and $5 in recent research. The updated fair value estimate of $26.20 reflects more cautious assumptions on revenue growth and profit margins, even as the projected future P/E edges higher.ナラティブの更新 • May 01
AZTA: 2026 Guidance And Space Research Partnership Will Support Sentiment Recovery
Azenta's updated analyst price target has moved modestly lower by about $0.77, as analysts factor in refreshed assumptions for fair value, discount rate, revenue growth, profit margin, and future P/E following a series of recent target cuts from major firms. Analyst Commentary Recent Street research has focused on recalibrating Azenta's fair value, with several firms trimming their price targets by between $5 and $10 as they reassess assumptions for growth, profitability, and appropriate P/E levels.ナラティブの更新 • Apr 15
AZTA: 2026 Guidance And Space Research Will Support Sentiment Recovery
Azenta's analyst price target has been trimmed by about $2.50 as analysts factor in updated assumptions for fair value, discount rate, revenue growth, profit margin, and future P/E following a series of recent target cuts from major firms. Analyst Commentary Recent Street research on Azenta points to a more cautious tone on valuation, with multiple price target trims clustering over a relatively short period.ナラティブの更新 • Apr 01
AZTA: 2026 Guidance And Space Research Tests Will Support Sentiment Recovery
Azenta's analyst price targets have been reduced by $5 to $9 in recent updates, as analysts factor in revised expectations for the diagnostic tools group and place greater emphasis on 2026 guidance and the clarity of the company's multi year growth framework. Analyst Commentary Recent research updates on Azenta show a mix of optimism around the long term framework and caution around the nearer term setup, with price targets adjusted both higher and lower as estimates and expectations are refreshed.Seeking Alpha • Mar 24
Azenta: Life Science Player Fails To Come To Life
Summary Azenta, Inc. trades near $20, with operating assets valued at just 0.5x sales and a robust net cash position around $600 million. Recent AZTA developments include the UK Biocentre acquisition and B Medical Systems divestiture, with the latter removing a key earnings drag. Despite a soft Q1 and margin pressure, Azenta maintains full-year guidance, supported by remediation efforts and interest income. The AZTA risk/reward is compelling at current levels, given low expectations, significant liquidity, and underappreciated asset value, making me a buyer despite above-average risks. Read the full article on Seeking Alphaナラティブの更新 • Mar 18
AZTA: 2026 Guidance And Space Research Partnership Will Support Sentiment Recovery
Azenta's analyst price targets have edged lower by a mid single digit dollar amount to around $39, as analysts factor in updated discount rate and growth assumptions, while still highlighting the importance of 2026 guidance and multi year frameworks for potential upside. Analyst Commentary Bullish Takeaways Bullish analysts point to the move to a US$39 price target as a reflection of clearer multi year planning, which supports their view that the company has several paths to grow into that valuation over time.ナラティブの更新 • Mar 03
AZTA: 2026 Framework And Buybacks Will Underpin Sentiment Recovery
Narrative Update: Azenta Azenta's latest analyst price targets have shifted slightly lower in recent research updates, with firms trimming their views by $5 and $9 after a prior increase to $39, as analysts factor in group wide adjustments in diagnostic tools and place more weight on visibility into the company's multi year framework and 2026 guidance. Analyst Commentary Recent research updates on Azenta reflect a mix of optimism about the long term setup and caution around execution and visibility, especially as analysts refresh their views on the broader diagnostic tools group and Azenta's multi year framework.
新しいナラティブ • Feb 25
Automation And Biorepositories Will Steadily Support A Fairly Valued Long Term Outlook
Catalysts About Azenta Azenta provides life sciences customers with sample management, biorepositories and multiomics services such as next-generation sequencing and gene synthesis. What are the underlying business or industry changes driving this perspective?ナラティブの更新 • Feb 17
AZTA: 2026 Margin Framework And Buybacks Will Support Future Upside
Analysts have trimmed their average price target on Azenta from about $43.50 to roughly $38.67, reflecting recent target cuts of $5 and $9, along with updated views on revenue growth, margins and a lower future P/E assumption. Analyst Commentary Recent research shows a mixed but detailed set of views around Azenta, with some focusing on long term growth potential and others dialing back expectations on valuation and near term execution.
新しいナラティブ • Feb 08
Multiomics Outsourcing And Automation Will Drive A Powerful Long Term Earnings Shift
Catalysts About Azenta Azenta provides life sciences customers with sample management, multiomics services and automation solutions across biorepositories, sequencing and gene synthesis. What are the underlying business or industry changes driving this perspective?ナラティブの更新 • Feb 03
AZTA: 2026 Margin Path And Buybacks Will Support Upside Potential
Analysts have nudged up their Azenta targets, with one moving to US$39 and another to US$45. This reflects interest in the company’s multi year growth framework and expectations for mid single digit organic revenue trends, with a path to margins above 20%.ナラティブの更新 • Jan 20
AZTA: Biopharma Exposure And 2026 Margin Path Support Balanced Risk Reward
Analysts have lifted their price target on Azenta to about US$43.50 from roughly US$40.17, citing slightly lower revenue growth expectations, firmer profit margin assumptions and a modestly lower future P/E outlook. The revised target is supported by recent research that notes improving sentiment, mid single digit organic revenue ambitions and a path to higher margins into 2026.ナラティブの更新 • Jan 05
AZTA: Biopharma Exposure Will Support Margin Expansion And 2026 Re Rating Potential
Analysts have nudged their fair value estimate for Azenta slightly higher to about $40, reflecting updated price targets in the mid to high $30s and low $40s, and their view that organic revenue growth and margin expansion potential into 2026 support a more constructive outlook on the shares. Analyst Commentary Recent research updates highlight a more constructive tone on Azenta, with several firms lifting price targets and turning more positive after the latest fiscal Q4 report and ahead of the upcoming investor day.ナラティブの更新 • Dec 14
AZTA: Biopharma Exposure Will Support Mid-Single-Digit Growth And Margin Expansion
Azenta's analyst price target has been raised by $10 to $45, as analysts point to mid single digit plus organic revenue growth prospects and a credible path to margins above 20% that is supported by healthy biopharma exposure and multiple growth drivers into 2026. Analyst Commentary Bullish analysts highlight that the latest results, while largely in line with expectations, reinforce confidence in Azenta's ability to sustain mid single digit plus organic revenue growth while steadily expanding margins above 20% over the medium term.ナラティブの更新 • Nov 29
AZTA: Mid-Single-Digit Organic Revenue Acceleration Will Broaden Profit Margins Into 2026
Azenta's analyst price target has increased from $35.17 to $39.83. Analysts cite in-line financial results and ongoing optimism around revenue growth and expanding profit margins, supported by sector exposure and long-term innovation opportunities.分析記事 • Nov 28
Azenta's (NASDAQ:AZTA) Earnings Offer More Than Meets The Eye
Investors signalled that they were pleased with Azenta, Inc.'s ( NASDAQ:AZTA ) most recent earnings report. Looking...ナラティブの更新 • Nov 14
AZTA: Growth Drivers From Biopharma Exposure And Acquisitions Will Unlock Opportunity
Analysts have raised their price target for Azenta from $30 to $38, citing expectations for increased growth opportunities and a positive outlook. This outlook is based on innovation, robust biopharma exposure, and prospective acquisitions.ナラティブの更新 • Oct 30
AZTA: Biopharma Demand and Acquisition Focus Will Drive Shares Higher Through 2026
Azenta's analyst price target has been raised from $33 to approximately $35.17 per share. Analysts cite increased confidence in the company's growth drivers and mid-term opportunities, particularly within the biopharma sector.分析記事 • Sep 12
Is There Now An Opportunity In Azenta, Inc. (NASDAQ:AZTA)?
While Azenta, Inc. ( NASDAQ:AZTA ) might not have the largest market cap around , it saw a decent share price growth of...分析記事 • Aug 07
Azenta, Inc. (NASDAQ:AZTA) Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates
NasdaqGS:AZTA 1 Year Share Price vs Fair Value Explore Azenta's Fair Values from the Community and select yours It's...分析記事 • Jul 24
Calculating The Fair Value Of Azenta, Inc. (NASDAQ:AZTA)
Key Insights Azenta's estimated fair value is US$38.26 based on 2 Stage Free Cash Flow to Equity Current share price of...新しいナラティブ • May 28
Pharma And Biotech Outsourcing Will Shape Future Market Dynamics
Strong industry trends and Azenta's infrastructure investments are driving above-market growth, recurring revenues, and operating leverage in sample management and biobanking.Seeking Alpha • Apr 17
Azenta: Life Science Business Failing To Come To Life
Summary Azenta, formerly Brooks Automation, has struggled to show organic growth and profitability, leading to a significant drop in its stock price. Despite a strong balance sheet and reduced valuation, the company needs to deliver real margin growth and profitability to attract investors. The company has faced challenges, including a decline in organic sales and the departure of its CEO, but continues to make strategic moves like selling B Medical Systems. Given the compressed sales multiples and strong cash position, a speculative position might be warranted, but management must prove its ability to improve earnings. Read the full article on Seeking Alpha分析記事 • Apr 05
Azenta, Inc.'s (NASDAQ:AZTA) 29% Share Price Plunge Could Signal Some Risk
Unfortunately for some shareholders, the Azenta, Inc. ( NASDAQ:AZTA ) share price has dived 29% in the last thirty...分析記事 • Mar 28
Are Investors Undervaluing Azenta, Inc. (NASDAQ:AZTA) By 50%?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Azenta fair value estimate is US$70.94 Current share price of...Seeking Alpha • Jan 27
Azenta: Taking A Pass
Summary Azenta, Inc. shares have surged over 30% since Nov 2024 due to S&P 600 inclusion and an analyst upgrade, despite somewhat tepid growth prospects. The company is restructuring to save $30-$40 million by FY26, divesting a business segment, and has a strong balance sheet. An analysis on Azenta, Inc. follows in the paragraphs below. Read the full article on Seeking Alpha分析記事 • Jan 10
At US$51.81, Is Azenta, Inc. (NASDAQ:AZTA) Worth Looking At Closely?
Azenta, Inc. ( NASDAQ:AZTA ), is not the largest company out there, but it received a lot of attention from a...分析記事 • Dec 20
A Look At The Intrinsic Value Of Azenta, Inc. (NASDAQ:AZTA)
Key Insights The projected fair value for Azenta is US$56.65 based on 2 Stage Free Cash Flow to Equity With US$49.50...分析記事 • Nov 17
Analysts Have Just Cut Their Azenta, Inc. (NASDAQ:AZTA) Revenue Estimates By 14%
The analysts covering Azenta, Inc. ( NASDAQ:AZTA ) delivered a dose of negativity to shareholders today, by making a...分析記事 • Nov 14
Shareholders Should Be Pleased With Azenta, Inc.'s (NASDAQ:AZTA) Price
It's not a stretch to say that Azenta, Inc.'s ( NASDAQ:AZTA ) price-to-sales (or "P/S") ratio of 3.1x right now seems...Seeking Alpha • Sep 11
Azenta: Life Science Play Is Not Coming To Life
Summary Azenta, Inc., formerly Brooks Automation, has struggled after the sale of its semiconductor business, as the remaining life sciences business has failed to turn a profit. Following aggressive share buybacks, Azenta's valuation remains demanding, with high earnings multiples and significant discrepancies between GAAP and non-GAAP earnings. New CEO John Marotta brings industry experience, but immediate results are unlikely, as the company needs to improve its margin profile and organic growth. I remain cautious on Azenta, monitoring its progress under new leadership, despite the seemingly low sales multiple and strong revenue base. Read the full article on Seeking Alpha株主還元
| AZTA | US Life Sciences | US 市場 | |
|---|---|---|---|
| 7D | 14.5% | 9.8% | 0.3% |
| 1Y | -17.1% | 17.2% | 19.9% |
業界別リターン: AZTA過去 1 年間で17.2 % の収益を上げたUS Life Sciences業界を下回りました。
リターン対市場: AZTAは、過去 1 年間で19.9 % のリターンを上げたUS市場を下回りました。
価格変動
| AZTA volatility | |
|---|---|
| AZTA Average Weekly Movement | 10.5% |
| Life Sciences Industry Average Movement | 8.7% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
安定した株価: AZTA 、 US市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。
時間の経過による変動: AZTAの 週次ボラティリティ ( 11% ) は過去 1 年間安定しています。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 1978 | 2,900 | John P. Marotta | www.azenta.com |
は、米国、中国、英国、その他の欧州諸国、アジア太平洋地域、および国際的なライフサイエンス業界向けに、生物学的および化学的化合物のサンプル探索および管理ソリューションを提供している。サンプルマネジメント・ソリューション部門とマルチオミクス部門を通じて事業を展開している。サンプルマネジメント・ソリューションズ事業では、自動化された保管庫、低温システム、自動化されたサンプルチューブ、消耗品、機器、制御された速度で解凍する機器などのサンプルマネジメント製品およびサービス、サンプルリポジトリサービスを提供している。また、実験計画から実施までのコンサルティングサービスも提供している。マルチオミクス事業では、遺伝子配列決定、遺伝子合成、および関連サービスからなるゲノムおよびその他のサンプル解析サービスを提供している。フロンティア・スペース社と戦略的パートナーシップを結び、宇宙での科学実験を実施している。前身はブルックス・オートメーション社で、2021年12月にアゼンタ社に社名変更した。アゼンタ・インクは1978年に設立され、マサチューセッツ州バーリントンに本社を置いている。
Azenta, Inc. 基礎のまとめ
| AZTA 基礎統計学 | |
|---|---|
| 時価総額 | US$1.18b |
| 収益（TTM） | -US$110.89m |
| 売上高(TTM) | US$596.48m |
2.0x
P/Sレシオ-10.6x
PER（株価収益率AZTA は割高か？
公正価値と評価分析を参照収益と収入
| AZTA 損益計算書（TTM） | |
|---|---|
| 収益 | US$596.48m |
| 売上原価 | US$332.07m |
| 売上総利益 | US$264.42m |
| その他の費用 | US$375.31m |
| 収益 | -US$110.89m |
直近の収益報告
Mar 31, 2026
次回決算日
該当なし
| 一株当たり利益（EPS） | -2.41 |
| グロス・マージン | 44.33% |
| 純利益率 | -18.59% |
| 有利子負債／自己資本比率 | 0% |
AZTA の長期的なパフォーマンスは？
過去の実績と比較を見る企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/06/29 17:37 |
| 終値 | 2026/06/29 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/09/30 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Azenta, Inc. 6 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。15
| アナリスト | 機関 |
|---|---|
| Christopher Muse | Barclays |
| Brett Hodess | BofA Global Research |
| Paul Knight | Brean Capital Historical (Janney Montgomery) |